跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 116 条关于
“xanomeline–trospium”
全部
116
临床试验
61
药物
6
机构
0
资讯
49
去年
Xanomeline/Trospium Chloride (COBENFY™) Approved for Schizophrenia Treatment
去年
Xanomeline Trospium Shows Promising Cognitive Benefits in Schizophrenia Patients with Baseline Impairment
去年
Xanomeline-Trospium Shows Consistent Efficacy in Schizophrenia Across Pooled Phase 3 Trials
去年
Xanomeline/Trospium (Cobenfy) Approved: A Novel Approach to Schizophrenia Treatment
去年
Xanomeline/Trospium Chloride Shows Cognitive Improvement in Schizophrenia; MindMed's LSD Trial Begins
去年
Bristol Myers Squibb Presents New COBENFY Data for Schizophrenia Treatment at Psych Congress
去年
Landmark Medical Advances of 2024: HIV Prevention, Schizophrenia Treatment, and More
去年
Cobenfy Shows Sustained Efficacy and Safety in Long-Term Schizophrenia Trials
2年前
FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors
去年
KarXT (Cobenfy) Approved for Schizophrenia: A Novel, Nondopaminergic Approach
第 1 页,共 5 页
上一页
下一页